Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study.

ABSTRACT:

Background

Chronotherapy is an innovative approach to improving survival through timed delivery of anti-cancer treatments according to patient daily rhythms. Temozolomide (TMZ) is a standard-of-care chemotherapeutic agent for glioblastoma (GBM). Whether timing of TMZ administration affects GBM patient outcome has not previously been studied. We sought to evaluate maintenance TMZ chronotherapy on GBM patient survival.

Methods

This retrospective study reviewed patients with newly diagnosed GBM from January 1, 2010 to December 31, 2018 at Washington University School of Medicine who had surgery, chemoradiation, and were prescribed TMZ to be taken in the morning or evening. The Kaplan-Meier method and Cox regression model were used for overall survival (OS) analyses. The propens

SUBMITTER: Damato AR 

PROVIDER: S-EPMC8086242 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature